Haselnuss Hal Allergy (Hazelnut)

Haselnuss Hal Allergy is employed primarily as a diagnostic tool to assess sensitization to hazelnut in patients suspected of having a food allergy.

• Skin prick testing to detect immediate‑type hypersensitivity to hazelnut.
• Confirmation of hazelnut allergy when clinical history is unclear.
• Differentiation of hazelnut allergy from other tree‑nut sensitivities.
• Guidance for dietary management and avoidance strategies.
• Support for clinicians in allergy clinics and specialist centers.

Skin testing with hazelnut extract may cause local reactions; most are mild and transient, while rare systemic responses can occur.

Common

• Redness at the test site.
• Small swelling or wheal formation.
• Itching or mild discomfort.
• Minor hives limited to the area of application.

Serious

• Large wheal or flare extending beyond the test site.
• Systemic urticaria.
• Respiratory symptoms such as wheezing or shortness of breath.
• Anaphylaxis (rare but requires immediate medical attention).

When using Haselnuss Hal Allergy, clinicians should observe several safety measures to minimize risk.

• Verify that the patient has no history of severe anaphylaxis to hazelnut before testing.
• Avoid testing on broken, inflamed, or infected skin.
• Ensure emergency equipment (e.g., epinephrine) is readily available.
• Use the product under the supervision of trained healthcare personnel.
• Consider age‑related guidelines; pediatric testing may require adjusted protocols.
• Document any prior antihistamine or medication use that could affect results.

Certain medications and conditions can influence the outcome of hazelnut skin testing or increase risk.

Avoid

• Antihistamines or other mast cell stabilizers taken within 48–72 hours, as they may suppress skin reactivity.
• Recent systemic corticosteroids that could diminish test responses.

Use with caution

• Beta‑blockers, which may interfere with treatment of severe reactions.
• Ongoing allergen immunotherapy, which could alter skin test sensitivity.
• ACE inhibitors, due to potential enhancement of angioedema.
• Patients with uncontrolled asthma, requiring careful monitoring during testing.